360 related articles for article (PubMed ID: 30072631)
1. Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4.
Bellmunt J
Biomedicines; 2018 Aug; 6(3):. PubMed ID: 30072631
[TBL] [Abstract][Full Text] [Related]
2. Sox4 Expression Confers Bladder Cancer Stem Cell Properties and Predicts for Poor Patient Outcome.
Shen H; Blijlevens M; Yang N; Frangou C; Wilson KE; Xu B; Zhang Y; Zhang L; Morrison CD; Shepherd L; Hu Q; Zhu Q; Wang J; Liu S; Zhang J
Int J Biol Sci; 2015; 11(12):1363-75. PubMed ID: 26681916
[TBL] [Abstract][Full Text] [Related]
3. 6p22.3 amplification as a biomarker and potential therapeutic target of advanced stage bladder cancer.
Shen H; Morrison CD; Zhang J; Underwood W; Yang N; Frangou C; Eng K; Head K; Bollag RJ; Kavuri SK; Rojiani AM; Li Y; Yan L; Hill A; Woloszynska-Read A; Wang J; Liu S; Trump DL; Candace JS
Oncotarget; 2013 Nov; 4(11):2124-34. PubMed ID: 24231253
[TBL] [Abstract][Full Text] [Related]
4. Amplification and overexpression of the ID4 gene at 6p22.3 in bladder cancer.
Wu Q; Hoffmann MJ; Hartmann FH; Schulz WA
Mol Cancer; 2005 May; 4(1):16. PubMed ID: 15876350
[TBL] [Abstract][Full Text] [Related]
5. Detailed Analysis of Focal Chromosome Arm 1q and 6p Amplifications in Urothelial Carcinoma Reveals Complex Genomic Events on 1q, and SOX4 as a Possible Auxiliary Target on 6p.
Eriksson P; Aine M; Sjödahl G; Staaf J; Lindgren D; Höglund M
PLoS One; 2013; 8(6):e67222. PubMed ID: 23825644
[TBL] [Abstract][Full Text] [Related]
6. Epithelial-to-mesenchymal transition based diagnostic and prognostic signature markers in non-muscle invasive and muscle invasive bladder cancer patients.
Singh R; Singh UP; Agrawal V; Garg M
Mol Biol Rep; 2022 Aug; 49(8):7541-7556. PubMed ID: 35593896
[TBL] [Abstract][Full Text] [Related]
7. Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors.
Heidenblad M; Lindgren D; Jonson T; Liedberg F; Veerla S; Chebil G; Gudjonsson S; Borg A; Månsson W; Höglund M
BMC Med Genomics; 2008 Jan; 1():3. PubMed ID: 18237450
[TBL] [Abstract][Full Text] [Related]
8. Human epidermal growth factor receptor 2 (
Agrawal V; Bharti N; Pandey R
Arab J Urol; 2020 Sep; 18(4):267-272. PubMed ID: 33312739
[TBL] [Abstract][Full Text] [Related]
9. The evolution of bladder cancer genomics: What have we learned and how can we use it?
Audenet F; Attalla K; Sfakianos JP
Urol Oncol; 2018 Jul; 36(7):313-320. PubMed ID: 29573965
[TBL] [Abstract][Full Text] [Related]
10. Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer.
Avgeris M; Tsilimantou A; Levis PK; Rampias T; Papadimitriou MA; Panoutsopoulou K; Stravodimos K; Scorilas A
Carcinogenesis; 2019 Aug; 40(8):965-974. PubMed ID: 30815670
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification.
Hurst CD; Tomlinson DC; Williams SV; Platt FM; Knowles MA
Oncogene; 2008 Apr; 27(19):2716-27. PubMed ID: 18037967
[TBL] [Abstract][Full Text] [Related]
12. Over expression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer.
Miyake H; Eto H; Arakawa S; Kamidono S; Hara I
J Urol; 2002 Mar; 167(3):1282-7. PubMed ID: 11832714
[TBL] [Abstract][Full Text] [Related]
13. Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.
Nassar AH; Umeton R; Kim J; Lundgren K; Harshman L; Van Allen EM; Preston M; Dong F; Bellmunt J; Mouw KW; Choueiri TK; Sonpavde G; Kwiatkowski DJ
Clin Cancer Res; 2019 Apr; 25(8):2458-2470. PubMed ID: 30593515
[TBL] [Abstract][Full Text] [Related]
14. Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.
Ferreira-Teixeira M; Paiva-Oliveira D; Parada B; Alves V; Sousa V; Chijioke O; Münz C; Reis F; Rodrigues-Santos P; Gomes C
BMC Med; 2016 Oct; 14(1):163. PubMed ID: 27769244
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of potential target genes of the 6p22.3-amplicon in urinary bladder cancer].
Oeggerli M; Schraml P; Novotny H; Sauter G; Simon R
Verh Dtsch Ges Pathol; 2005; 89():219-24. PubMed ID: 18035695
[TBL] [Abstract][Full Text] [Related]
16. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
[TBL] [Abstract][Full Text] [Related]
17. WNT/β-catenin signaling in urothelial carcinoma of bladder.
Garg M; Maurya N
World J Nephrol; 2019 Sep; 8(5):83-94. PubMed ID: 31624709
[TBL] [Abstract][Full Text] [Related]
18. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer.
Oeggerli M; Tomovska S; Schraml P; Calvano-Forte D; Schafroth S; Simon R; Gasser T; Mihatsch MJ; Sauter G
Oncogene; 2004 Jul; 23(33):5616-23. PubMed ID: 15122326
[TBL] [Abstract][Full Text] [Related]
19. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
20. Epithelial-To-Mesenchymal Transition and Its Correlation With Clinicopathologic Features in Patients With Urothelial Carcinoma of the Bladder.
Singh R; Ansari JA; Maurya N; Mandhani A; Agrawal V; Garg M
Clin Genitourin Cancer; 2017 Apr; 15(2):e187-e197. PubMed ID: 27601277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
